Clinical trial
Rituximab in Active Ulcerative Colitis
NCT00261118 · Royal Liverpool University Hospital, Other · Completed
Key facts
| NCT number | NCT00261118 |
|---|---|
| Title | Rituximab in Active Ulcerative Colitis |
| Official title | Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis |
| Lead sponsor | Royal Liverpool University Hospital, Other |
| Collaborators | Hoffmann-La Roche Industry University of Liverpool |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 24 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 2, 2005 |
| Last update posted | Nov 6, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: